Progesterone receptor expression and its prognostic role in hormone receptor-positive/human epidermal growth factor receptor 2-positive breast cancer: a retrospective cohort study
Open Access
- 1 January 2026
- journal article
- breast
- Published by XMLink in Annals of Surgical Treatment and Research
- Vol. 110 (2) , 112-118
Abstract
While progesterone receptor (PR) negativity in luminal-type breast cancer is generally associated with worse oncologic outcomes, its prognostic role in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains underexplored. This study aimed to evaluate the prognostic significance of PR expression in ER-positive, HER2-positive breast cancer. A retrospective analysis was conducted on patients diagnosed with ER-positive, HER2-positive breast cancer who underwent primary surgery at Korea University Guro Hospital between January 2009 and December 2019. Patients were grouped by PR expression as negative/low (Allred score, 0–6) or strongly positive (Allred score,7 or 8). Prognostic outcomes, including disease-free survival (DFS), distant recurrence-free survival (DRFS), and breast cancer-specific survival (BCSS) were analyzed. A total of 223 patients were included. Patients in the negative/low PR group were older compared to the strongly positive PR group. The negative/low PR group showed significantly worse DFS (P = 0.005) and DRFS (P = 0.014) but showed no significant difference in BCSS (P = 0.153). On multivariate analysis, negative or low PR expressions were linked to inferior DFS (hazard ratio [HR], 3.10; 95% confidence interval [CI], 1.34–7.16; P = 0.008) and DRFS (HR, 9.55; 95% CI, 1.22–74.77; P = 0.032). In ER-positive, HER2-positive breast cancer, negative or weak PR expression was associated with inferior DFS and DRFS compared to strong PR expression. These findings highlight the potential prognostic value of PR status in this group, underscoring its relevance in guiding treatment and follow-up strategies for more individualized patient care.Keywords
This publication has 29 references indexed in Scilit:
- The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐upCancer, 2023
- Should triple-positive breast cancer be recognized as a distinct subtype?Expert Review of Anticancer Therapy, 2020
- Progesterone receptor modulates ERα action in breast cancerNature, 2015
- Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and researchBreast Cancer Research and Treatment, 2014
- Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Annals of Oncology, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010The Breast, 2012
- Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patientsCancer, 2011
- Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancerBreast Cancer Research and Treatment, 2007
- Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen TherapyBreast Cancer Research and Treatment, 2002